文献速递抗栓抗凝管理特殊人群用药

直接口服抗凝药在儿科患者中的应用

Just DOAC: Use of direct-acting oral anticoagulants in pediatrics.
PubMed 文献 · Am J Health Syst Pharm · 2023-01-01

本文综述了直接口服抗凝药(DOAC)在儿科患者中的现有文献并总结正在进行的试验。证据支持达比加群和利伐沙班用于儿童静脉血栓栓塞症(VTE)治疗,疗效与标准治疗相当且出血风险相似;利伐沙班在儿童脑静脉血栓及中心静脉导管相关VTE中安全有效。儿童VTE防治文献不断增多,但仍需循证指南及长期上市后研究。

要点

  • 达比加群和利伐沙班可用于儿童VTE治疗,疗效非劣于标准治疗且出血率相似。
  • 利伐沙班用于儿童脑静脉血栓和中心静脉导管相关VTE安全有效。
  • 达比加群用于儿童VTE预防安全性良好,利伐沙班用于先天性心脏病患儿VTE预防安全性良好。

核心结论

  • 儿科VTE治疗与预防的文献不断增多,但仍需循证儿科指南。
  • 需要更多长期上市后研究以阐明在临床试验排除场景中的安全性和有效性。
  • 关于逆转剂的安全性、有效性和给药策略的数据仍不足,尤其在DOAC在儿科人群中使用日益普遍的背景下。

研究设计与样本

  • 本文为综述,旨在概述当前DOAC在儿科患者中使用的文献并总结正在进行的试验。

主要发现

  • 达比加群在疗效方面非劣于标准治疗,出血率相似。
  • 利伐沙班治疗儿童急性VTE复发风险低、血栓负荷减轻,且与标准治疗相比未增加出血风险。
  • 利伐沙班治疗儿童脑静脉血栓及中心静脉导管相关VTE安全有效,与标准治疗相似。
  • 达比加群用于VTE预防安全性良好,利伐沙班用于先天性心脏病患儿VTE预防安全性良好。
  • 多种DOAC的多项研究正在进行,评估特殊患者人群的安全性和有效性及VTE预防。

临床怎么用

  • 儿科VTE治疗可考虑使用达比加群或利伐沙班,证据支持其疗效与标准治疗相当且出血风险相似。
  • 儿童脑静脉血栓或中心静脉导管相关VTE可考虑使用利伐沙班。
  • 先天性心脏病患儿VTE预防可考虑利伐沙班。

局限性

  • 仍需循证儿科指南。
  • 需要更多长期上市后研究以阐明临床试验排除场景中的安全性和有效性。
  • 逆转剂的安全性、有效性和给药策略数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this article is to provide an overview of the current literature for direct-acting oral anticoagulant (DOAC) use in pediatric patients and summarize ongoing trials. SUMMARY: In treatment of venous thromboembolism (VTE) in pediatric patients, evidence supports use of both dabigatran and rivaroxaban. Dabigatran has been shown to be noninferior to standard of care (SOC) in terms of efficacy, with similar bleeding rates. Similarly, treatment with rivaroxaban in children with acute VTE resulted in a low recurrence risk and reduced thrombotic burden, without increased risk of bleeding, compared to SOC. Treatment of pediatric cerebral venous thrombosis as well as central venous catheter-related VTE with rivaroxaban appeared to be both safe and efficacious and similar to that with SOC. Dabigatran also has a favorable safety profile for prevention of VTE, and rivaroxaban has a favorable safety profile for VTE prevention in children with congenital heart disease. Many studies with several different DOACs are ongoing to evaluate both safety and efficacy in unique patient populations, as well as VTE prevention. CONCLUSION: The literature regarding pediatric VTE treatment and prophylaxis is growing, but the need for evidence-based pediatric guidelines remains. Additional long-term, postauthorization studies are warranted to further elucidate safety and efficacy in clinical scenarios excluded in clinical trials. Additional data on safety, efficacy, and dosing strategies for reversal agents are also necessary, especially as the use of DOACs becomes more common in the pediatric population.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Mills K, Hill C, King M, et al. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics. Am J Health Syst Pharm. 2023. PMID: 36610740. doi:10.1093/ajhp/zxac387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。